Do analysts rate BIOL or VVOS?

Vivos Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 1,615.69%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than BIOLASE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is BIOL or VVOS more profitable?

BIOLASE has a net margin of -41.65% compared to Vivos Therapeutics' net margin of -122.00%. BIOLASE's return on equity of -1,782.73% beat Vivos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Vivos Therapeutics -122.00% -2,325.64% -102.01%

Do analysts rate VRAX or BIOL?

Virax Biolabs Group presently has a consensus price target of $25.00, suggesting a potential upside of 884.25%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts clearly believe Virax Biolabs Group is more favorable than BIOLASE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, VRAX or BIOL?

Virax Biolabs Group has higher earnings, but lower revenue than BIOLASE. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 203.20 -$5.02M N/A N/A BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A

Which has better valuation & earnings, BIOL or BTCY?

Biotricity has lower revenue, but higher earnings than BIOLASE. Biotricity is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A Biotricity $12.06M 0.14 -$14.09M -$0.14 N/A

Is BIOL or BTCY more profitable?

BIOLASE has a net margin of -41.65% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Biotricity -80.42% N/A -188.47%

Do analysts prefer GCTK or BIOL?

Given BIOLASE's higher possible upside, analysts clearly believe BIOLASE is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GCTK or BIOL more profitable?

GlucoTrack has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. BIOLASE's return on equity of -1,782.73% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -2,135.52% -290.22% BIOLASE -41.65% -1,782.73% -55.31%

Do analysts prefer BIOL or BBLG?

Given BIOLASE's higher possible upside, equities research analysts plainly believe BIOLASE is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BIOL or BBLG more profitable?

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -57.87% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Bone Biologics N/A -57.87% -53.65%

BIOLASE (BIOL) Competitors

Compare

BIOL vs. VVOS, VRAX, BTCY, GCTK, and BBLG

Should you buy BIOLASE stock or one of its competitors? BIOLASE's main competitors and comparable companies include Vivos Therapeutics (VVOS), Virax Biolabs Group (VRAX), Biotricity (BTCY), GlucoTrack (GCTK), and Bone Biologics (BBLG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does BIOLASE compare to Vivos Therapeutics?

BIOLASE (NASDAQ:BIOL) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Vivos Therapeutics'average media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Vivos Therapeutics	Neutral

BIOLASE has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Vivos Therapeutics	$17.44M	0.13	-$21.17M	-$1.90	N/A

BIOLASE has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.04, suggesting that its share price is 504% more volatile than the broader market.

Vivos Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 1,615.69%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than BIOLASE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

BIOLASE has a net margin of -41.65% compared to Vivos Therapeutics' net margin of -122.00%. BIOLASE's return on equity of -1,782.73% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

Summary

Vivos Therapeutics beats BIOLASE on 7 of the 13 factors compared between the two stocks.

How does BIOLASE compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Virax Biolabs Group's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
BIOLASE	Neutral

Virax Biolabs Group has higher earnings, but lower revenue than BIOLASE.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	203.20	-$5.02M	N/A	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

Virax Biolabs Group has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Virax Biolabs Group's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
BIOLASE	-41.65%	-1,782.73%	-55.31%

Virax Biolabs Group has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 0.3% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Virax Biolabs Group presently has a consensus price target of $25.00, suggesting a potential upside of 884.25%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts clearly believe Virax Biolabs Group is more favorable than BIOLASE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Virax Biolabs Group beats BIOLASE on 9 of the 11 factors compared between the two stocks.

How does BIOLASE compare to Biotricity?

BIOLASE (NASDAQ:BIOL) and Biotricity (NASDAQ:BTCY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Biotricity has lower revenue, but higher earnings than BIOLASE. Biotricity is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Biotricity	$12.06M	0.14	-$14.09M	-$0.14	N/A

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Comparatively, 1.6% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Biotricity	Neutral

BIOLASE has a net margin of -41.65% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Biotricity	-80.42%	N/A	-188.47%

BIOLASE has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Summary

BIOLASE and Biotricity tied by winning 5 of the 10 factors compared between the two stocks.

How does BIOLASE compare to GlucoTrack?

GlucoTrack (NASDAQ:GCTK) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

GlucoTrack has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. BIOLASE's return on equity of -1,782.73% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-2,135.52%	-290.22%
BIOLASE	-41.65%	-1,782.73%	-55.31%

GlucoTrack has higher earnings, but lower revenue than BIOLASE. GlucoTrack is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

In the previous week, GlucoTrack had 2 more articles in the media than BIOLASE. MarketBeat recorded 2 mentions for GlucoTrack and 0 mentions for BIOLASE. GlucoTrack's average media sentiment score of 0.66 beat BIOLASE's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Overall Sentiment
GlucoTrack	Positive
BIOLASE	Neutral

GlucoTrack has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Given BIOLASE's higher possible upside, analysts clearly believe BIOLASE is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 5.9% of GlucoTrack shares are held by insiders. Comparatively, 0.3% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

GlucoTrack and BIOLASE tied by winning 7 of the 14 factors compared between the two stocks.

How does BIOLASE compare to Bone Biologics?

BIOLASE (NASDAQ:BIOL) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -57.87% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Bone Biologics	N/A	-57.87%	-53.65%

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by insiders. Comparatively, 5.0% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bone Biologics has lower revenue, but higher earnings than BIOLASE. Bone Biologics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A

BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Given BIOLASE's higher possible upside, equities research analysts plainly believe BIOLASE is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Bone Biologics	Neutral

Summary

Bone Biologics beats BIOLASE on 9 of the 12 factors compared between the two stocks.

Get BIOLASE News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOL vs. The Competition

Export

Metric	BIOLASE	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$581K	$5.57B	$7.24B	$13.21B
Dividend Yield	N/A	1.80%	2.57%	12.80%
P/E Ratio	0.00	25.34	275.49	25.40
Price / Sales	N/A	43.73	639.63	86.88
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	N/A	5.69	10.46	6.33
Net Income	-$20.63M	$151.55M	$3.49B	$358.33M

BIOLASE Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160
VVOS Vivos Therapeutics	1.6883 of 5 stars	$0.16 -1.5%	$2.80 +1,638.1%	-95.3%	$2.27M	$17.44M	N/A	160
VRAX Virax Biolabs Group	2.7237 of 5 stars	$2.49 -3.9%	$25.00 +904.0%	-83.8%	$2.06M	$10K	N/A	5	Positive News
BTCY Biotricity	N/A	$0.09 -3.1%	N/A	-86.6%	$1.86M	$12.06M	N/A	40	Gap Up
GCTK GlucoTrack	0.9741 of 5 stars	$2.24 -1.3%	N/A	-97.5%	$1.60M	N/A	N/A	5	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOL) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BIOLASE (BIOL) Competitors

BIOL vs. VVOS, VRAX, BTCY, GCTK, and BBLG

How does BIOLASE compare to Vivos Therapeutics?

Summary

How does BIOLASE compare to Virax Biolabs Group?

Summary

How does BIOLASE compare to Biotricity?

Summary

How does BIOLASE compare to GlucoTrack?

Summary

How does BIOLASE compare to Bone Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BIOLASE (BIOL) Competitors

BIOL vs. VVOS, VRAX, BTCY, GCTK, and BBLG

How does BIOLASE compare to Vivos Therapeutics?

Do insiders & institutionals hold more shares of BIOL or VVOS?

Does the media refer more to BIOL or VVOS?

Which has better valuation & earnings, BIOL or VVOS?

Which has more volatility and risk, BIOL or VVOS?

Do analysts rate BIOL or VVOS?

Is BIOL or VVOS more profitable?

Summary

How does BIOLASE compare to Virax Biolabs Group?

Does the media favor VRAX or BIOL?

Which has better valuation & earnings, VRAX or BIOL?

Is VRAX or BIOL more profitable?

Which has more volatility & risk, VRAX or BIOL?

Do insiders and institutionals have more ownership in VRAX or BIOL?

Do analysts rate VRAX or BIOL?

Summary

How does BIOLASE compare to Biotricity?

Which has better valuation & earnings, BIOL or BTCY?

Do insiders and institutionals believe in BIOL or BTCY?

Does the media prefer BIOL or BTCY?

Is BIOL or BTCY more profitable?

Which has more volatility & risk, BIOL or BTCY?

Summary

How does BIOLASE compare to GlucoTrack?

Is GCTK or BIOL more profitable?

Which has higher earnings and valuation, GCTK or BIOL?

Does the media prefer GCTK or BIOL?

Which has more volatility & risk, GCTK or BIOL?

Do analysts prefer GCTK or BIOL?

Do institutionals and insiders believe in GCTK or BIOL?

Summary

How does BIOLASE compare to Bone Biologics?

Is BIOL or BBLG more profitable?

Do institutionals & insiders hold more shares of BIOL or BBLG?

Which has better valuation and earnings, BIOL or BBLG?

Which has more volatility and risk, BIOL or BBLG?

Do analysts prefer BIOL or BBLG?

Does the media refer more to BIOL or BBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools